The case for vaccine development in the strategy to eradicate river blindness (onchocerciasis) from Africa

Expert Review of Vaccines

Volumn 14, Issue 9, 2015, Pages 1163-1165

  Makepeace, Benjamin L ^a   Babayan, Simon A ^b   Lustigman, Sara ^c   Taylor, David W ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c NEW YORK BLOOD CENTER   (United States)

Author keywords

cysteine proteinase inhibitor; filarial nematodes; immunoprophylaxis; Loa; Onchocerca volvulus

Indexed keywords

ONCHOCERCIASIS VACCINE; RECOMBINANT ANTIGEN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VACCINE;

AFRICA; BOVINE; DNA IMMUNIZATION; EUROPE; FUNDING; HUMAN; IMMUNOMODULATION; INFECTION CONTROL; MICROFILARIA (NEMATODE LARVA); NONHUMAN; ONCHOCERCA; ONCHOCERCA OCHENGI; ONCHOCERCA VOLVULUS; ONCHOCERCIASIS; PARASITE CLEARANCE; PARASITE CONTROL; PARASITE IMMUNITY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SCALE UP; TREATMENT OUTCOME; UNITED STATES; VACCINE PRODUCTION; DISEASE TRANSMISSION; DRUG DEVELOPMENT; IMMUNOLOGY; IMMUNOTHERAPY; INTERNATIONAL COOPERATION; ISOLATION AND PURIFICATION; ONCHOCERCIASIS, OCULAR; PREVENTION AND CONTROL; PROCEDURES; TRENDS;

DISEASE TRANSMISSION, INFECTIOUS; DRUG DISCOVERY; HUMANS; IMMUNOTHERAPY; INTERNATIONAL COOPERATION; ONCHOCERCIASIS, OCULAR; VACCINES;

EID: 84939445609     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2015.1059281     Document Type: Review

References (21)

1. Hotez PJ, Alvarado M, Basanez MG, et al. The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases. PLoS Negl Trop Dis 2014;8:e2865
2. Working to overcome the global impact of neglected tropical diseases: First WHO report on neglected tropical diseases. Crompton DW, Peters P, Editors. World Health Organisation; Geneva: 2010
3. Crump A, Morel CM, Omura S. The onchocerciasis chronicle: from the beginning to the end? Trends Parasitol 2012;28:280-8
4. Elimination of onchocerciasis in the WHO Region of the Americas: Ecuador's progress towards verification of elimination. Wkly Epidemiol Rec 2014;89:401-5
5. Dadzie Y, Neira M, Hopkins D. Final report of the Conference on the eradicability of Onchocerciasis. Filaria J 2003;2:2
6. Diawara L, Traore MO, Badji A, et al. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLoS Negl Trop Dis 2009;3: e497
7. Conceptual and operational framework of onchocerciasis elimination with ivermectin treatment. Ouagadougou: African Programme for Onchocerciasis Control, 2010
8. Accelerating work to overcome the global impact of neglected tropical diseases: A roadmap for implementation. Crompton DW, Editor. World Health Organisation; Geneva: 2012
9. Mectizan Donation Program: What we do. Decatur, GA: Mectizan Donation Program, 2015. Available from: http://www.mectizan.org/about/what-we-do [Last accessed 8 April 2015]
10. Kim YE, Remme JH, Steinmann P, et al. Control, elimination, and eradication of river blindness: scenarios, timelines, and ivermectin treatment needs in Africa. PLoS Negl Trop Dis 2015;9:e0003664
11. Katabarwa MN, Lakwo T, Habomugisha P, et al. Transmission of Onchocerca volvulus continues in Nyagak-Bondo focus of northwestern Uganda after 18 Years of a single dose of annual treatment with ivermectin. Am J Trop Med Hyg 2013;89: 293-300
12. Wanji S, Kengne-Ouafo JA, Esum ME, et al. Situation analysis of parasitological and entomological indices of onchocerciasis transmission in three drainage basins of the rain forest of south west cameroon after a decade of ivermectin treatment. Parasit Vectors 2015;8:202
13. Osei-Atweneboana MY, Eng JK, Boakye DA, et al. Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. Lancet 2007;369:2021-9
14. Nana-Djeunga HC, Bourguinat C, Pion SD, et al. Reproductive status of Onchocerca volvulus after ivermectin treatment in an ivermectin-naive and a frequently treated population from Cameroon. PLoS Negl Trop Dis 2014;8:e2824
15. Taylor MJ, Hoerauf A, Townson S, et al. Anti-Wolbachia drug discovery and development: safe macrofilaricides for onchocerciasis and lymphatic filariasis. Parasitology 2014;141:119-27
16. Makepeace BL, Jensen SA, Laney SJ, et al. Immunisation with a multivalent, subunit vaccine reduces patent infection in a natural bovine model of onchocerciasis during intense field exposure. PLoS Negl Trop Dis 2009;3:e544
17. Babayan SA, Luo H, Gray N, et al. Deletion of parasite immune modulatory sequences combined with immune activating signals enhances vaccine mediated protection against filarial nematodes. PLoS Negl Trop Dis 2012;6:e1968
18. Hess JA, Zhan B, Bonne-Annee S, et al. Vaccines to combat river blindness: expression, selection and formulation of vaccines against infection with Onchocerca volvulus in a mouse model. Int J Parasitol 2014;44:637-46
19. Arumugam S, Wei J, Ward D, et al. Vaccination with a genetically modified Brugia malayi cysteine protease inhibitor-2 reduces adult parasite numbers and affects the fertility of female worms following a subcutaneous challenge of Mongolian gerbils (Meriones unguiculatus) with B. malayi infective larvae. Int J Parasitol 2014;44:675-9
20. Onchocerca volvulus (PRJEB513). [WormBase ParaSite]. Hinxton, Cambridge, UK: EMBL - EBI 2015. Available from: http://parasite.wormbase.org/Onchocerca-volvulus-prjeb513/Info/Index/ [Last accessed 8 April 2015]
21. Hotez PJ, Bottazzi ME, Zhan B, et al. The onchocerciasis vaccine for africa-TOVA-initiative. PLoS Negl Trop Dis 2015;9: e0003422